IRVING, Texas–(BUSINESS WIRE)–The End Drug Shortages Alliance (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer. Akorn Pharmaceuticals filed for bankruptcy Feb. 23 and ceased all U.S. manufacturing operations, leaving questions about the impact to the supply of over 100 medications — some … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Europe Single Cell Multiomics Market 2021-2031 by Product Type, Omics Type, Application, Sample Type, Workflow, End User, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering. Europe single cell multiomics market was valued at $ 527.9 million in 2021 and will grow by 18.0% annually over 2021-2031, driven … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report By Test Type (Tuberculin Skin Test (TST), Interferon-Gamma Released Assay (IGRA)), By Application, By End User, By Region, And Segment Forecasts, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering. The global latent tuberculosis infection detection market size is expected to … [Read more…]
Technologies Like Masimo SpHb® Offer a “Practical Approach” to Perioperative Blood Management and “Timely Detection of Changes” NEUCHATEL, Switzerland–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) today announced that updated guidelines published by the European Society of Anaesthesiology and Intensive Care (ESAIC) highlight the value of noninvasive, continuous hemoglobin (Hb) monitoring in helping clinicians manage perioperative bleeding. Referencing studies … [Read more…]
LYON, France–(BUSINESS WIRE)–Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the NASH Renaissance virtual event hosted by Evercore ISI on Thursday, March 30, 2023. The Company … [Read more…]
Efficacy and Safety profile of LUMEVOQ® confirmed in a real-world setting Improvement of visual acuity of +22.5 ETDRS letters vs nadir at one year Data presented at the NANOS 2023 Annual Meeting, March 14 PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene … [Read more…]
New Phase I data confirm high immunogenicity and promising efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation Exciting preclinical data on the novel IV oncolytic virus candidate TG6050 STRASBOURG, France–(BUSINESS WIRE)–#HBV–Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies … [Read more…]
MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced a non-cash impairment of its goodwill and intangible oncology assets. This impairment comes as a result of the Company’s … [Read more…]
WATSONVILLE, Calif.–(BUSINESS WIRE)–#EatMoreProduce—Peer reviewed research published in the Journal of Toxicology found that the recommendation in the “Dirty Dozen” list to substitute organic forms of produce for conventional do not result in any decrease in risk for consumers because residues on conventionally grown are so low, if present at all. The research also found that … [Read more…]
WILMINGTON, Del.–(BUSINESS WIRE)–$INCY–Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida. “As Incyte continues to advance research in areas where we believe we can have the biggest impact for patients, we … [Read more…]
